New direct oral anticoagulants – current therapeutic options and treatment recommendations for bleeding complications

Summary

To date, clinical studies show that the incidence of spontaneous bleeding with new direct oral anticoagulants (DOAs) is comparable to that of established anticoagulants. However, unlike vitamin K antagonists, there are currently no clinically available antidotes or approved reversal agents for new DOAs. Restoring normal coagulation is important in many cases, such as emergency surgeries, serious bleedings, or anticoagulant overdosing. Attempts have been made to restore normal coagulation after treatment with new DOAs using compounds such as recombinant activated factor VII (rFVIIa), prothrombin complex concentrate (PCC), or FEIBA (factor eight inhibitor bypassing activity). Limited pre-clinical data and even less clinical evidence are available on the usefulness of these methods in restoring normal coagulation for the emergency management of critical bleeding episodes. Evaluating the utility of DOAs is further complicated by the fact that it is unknown how predictive established test systems are of the bleeding risks. Clinical practice requires further evaluation of the emergency management options for the new DOAs to define the agents and the doses that are most useful. Furthermore, patients receiving long-term treatment with a DOA are likely to undergo elective surgery at some point, and there is lack of evidence regarding perioperative treatment regimens under such conditions. This review summarises potential bleeding management options and available data on the new DOAs.

Keywords

Prophylactic anticoagulation - oral anticoagulant - bleeding complication - treatment recommendation

• References

• 1 Wardrop D, Keeling D. The story of the discorvery of heparin and warfarin. Br J Haematology 2008; 141: 757-763.
• 2 Camm AJ, Kirchhof P, Lip GY. et al. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial ?brillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
• 3 Alban S. From heparins to factor Xa inhibitors and beyond. Eur J Clin Invest 2005; 35 (Suppl. 01) 12-20.
• 4 Hirsh J, Bauer KA, Donati MB. et al. Parenteral Anticoagulants. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Ed.). Chest 2008; 133: 141S-159S.
• 5 Suranyi M, Chow JSF. Review: Anticoagulation for haemodialysis. Nephrology 2010; 15: 386-392.
• 6 Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008; 451: 914-918.
• 7 Heit JA. The Epidemiology of Venous Thromboembolism in the Community. Arterioscler Thromb Vasc Biol 2008; 28: 370-372.
• 8 Lip GYH, Andreotti F, Fauchier L. et al. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011; 106: 997-1011.
• 9 Lakshminarayan K, Anderson DC, Herzog CA. et al. Clinical epidemiology of atrial fibrillation and related cerebrovascular events in the United States. Neurologist 2008; 14: 143-150.
• 10 Lanes S, Fraeman K, Meyers A. et al. Incidence rates for thromboembolic, bleeding and hepatic outcomes in patients undergoing hip or knee replacement surgery. J Thromb Haemost 2011; 09: 325-332.
• 11 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. Engl J Med 2009; 361: 1139-1151.
• 12 Oldgren J, Alings M, Darius H. et al. on behalf of the RE-LY Investigators. Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS2 Score: A Subgroup Analysis of the RE-LY Trial. Ann Intern Med. 2011 155. 660-667.
• 13 Ansell J. Bleeding in Very Old Patients on Vitamin K Antagonist Therapy. Circulation 2011; 124: 769-771.
• 14 Palareti G. Bleeding with anticoagulant treatments. Hämostaseologie 2011; 31: 237-242.
• 15 Mant J, Hobbs FD, Fletcher K. et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493-503.
• 16 van Walraven C, Hart RG, Singer DE. et al. Oral anticoagulants vs aspirin in non-valvular atrial fibrillation: an individual patient meta-analysis. J Am Med Assoc 2002; 288: 2441-2448.
• 17 Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 03: 692-694.
• 18 Eikelboom JW, Wallentin L, Connolly SJ. et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363-2372.
• 19 Rosencher N, Zufferey P, Samama CM. Definition of major bleeding in surgery: an anesthesiologist's point of view: a rebuttal. J Thromb Haemost. 2010 08. 1442-1443 author reply 1443–1444.
• 20 Ansell J. Factor Xa or thrombin: is factor Xa a better target?. J Thromb Haemost 2007; 05 (Suppl. 01) 60-64.
• 21 Goldsack R, Chambers RC, Dabbagh K. et al. Thrombin. Int J Biochem Cell Biol 1998; 30: 641-646.
• 22 Moser M, Bode C. Anticoagulation in atrial fibrillation – A new era has begun. Hamostaseologie 2012; 32: 37-39.
• 23 Marijon E, Fauchier L, Le Heuzey JY. New antithrombotic drugs and European approval processes. Lancet 2011; 378: 662-663.
• 24 Eriksson BI, Quinlan DJ, Eikelboom JW. Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism. Ann Rev Med 2011; 62: 41-57.
• 25 Guyatt GH, Akl EA, Crowther M. et al. Antithrombotic Therapy and Prevention of Thrombosis.American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th ed.). Chest 2012; 141 (Suppl. 02) 7S-47S.
• 26 Ganetsky M, Babu KM, Salhanick SD. et al. Dabigatran: Review of Pharmacology and Management of Bleeding Complications of This Novel Oral Anticoagulant. J Med Toxicol 2011; 07: 281-287.
• 27 Harder S. Renal Profiles of Anticoagulants. J Clin Pharmacol 2012; 52: 964-975.
• 28 FDA Drug Safety Communication. Safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate mesylate). Available at: http://www.fda.gov/Drugs/DrugSafety/ucm282724.htm#pat Accessed April 2012
• 29 Kwong LM. Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial data. Vasc Health Risk Manag 2011; 07: 461-466.
• 30 Xarelto Summary of Product Characteristics. Available at: http://www.xarelto.com/en/information-on-xarelto/summary-of-product-characteristics Accessed April 2012
• 31 Tzeis S, Andrikopoulos G. Novel Anticoagulants for Atrial Fibrillation: A Critical Appraisal. Angiology 2012; 63: 164-170.
• 32 Eliquis Summary of Product Characteristics. Available at: http://www.eliquis.eu/eliquis_smpc.aspx Accessed April 2012
• 33 Cabral KP, Ansell J, Hylek EM. Future directions of stroke prevention in atrial ?brillation: the potential impact of novel anticoagulants and stroke risk strati?cation. J Thromb Haemost 2011; 09: 441-449.
• 34 Pradaxa, summary of product characteristics. Available at: http://www.pradaxa.com Accessed April 2012
• 35 Ogata K, Mendell- Harary J, Tachibana M. et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010; 50: 743-753.
• 36 Harenberg J, Jörg I, Weiss C. Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. Int J Toxicol 2006; 25: 165-169.
• 37 Kubitza D, Becka M, Wensing G. et al. Safety, pharmacodynamis and pharmacokinetics of BAY 59–7939 – an oral direct factor Xa inhibitor – after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873-880.
• 38 Levine MN, Raskob G, Beyth RJ. et al. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (03) Suppl 287S-310S.
• 39 Friedman RJ, Dahl OE, Rosencher N. et al. RE-MOBILIZE, RE-MODEL, RE-NOVATE Steering Committees. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res. 2010 126. 175-182.
• 40 Flaker G, Ezekowitz M, Yusuf S. et al. Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study. J Am Coll Cardiol 2012; 59: 854-855.
• 41 APPRAISE Steering Committee and Investigators. Alexander JH, Becker RC, Bhatt DL. et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009 119. 2877-2885.
• 42 Granger CB, Alexander JH, McMurray JJV. et al. for the ARISTOTLE Committees and Investigators. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2011 365. 981-992.
• 43 Poli D, Antonucci E, Grifoni E. et al. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol 2009; 54: 999-1002.
• 44 Tafur AJ, McBane 2nd R, Wysokinski WE. et al. Predictors of Major Bleeding in Peri-Procedural Anticoagulation Management. J Thromb Haemost 2012; 10: 261-267.
• 45 Freyburger G, Macouillard G, Labrouche S. et al. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 2011; 127: 457-465.
• 46 Mani H, Hesse C, Stratmann G. et al. Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. Thromb Haemost 2011; 106: 156-164.
• 47 Douxfils J, Mullier F, Robert S. et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Thromb Haemost 2012; 107: 985-997.
• 48 Ahrens I, Lip GYH, Peter K. Anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104: 49-60.
• 49 Samama MM, Martinoli JL, LeFlem L. et al. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 103: 815-825.
• 50 Levi MM, Eerenberg E, Löwenberg E. et al. Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management. Neth J Med 2010; 68: 68-76.
• 51 Perzborn E, Trabandt A, Selbach K. et al. Prothrombin complex concentrate reverses the effect of high doses of high dose rivaroxaban in rats. Pathophysiol Haemost Thromb 2010; 37: YA10-OC251.
• 52 Eerenberg ES, Kamphuisen PW, Sijpkens MK. et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.
• 53 van Ryn J, Stangier J, Haertter S. et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
• 54 Zhou W, Schwarting S, Illanes S. et al. Hemostatic therapy in experimental intra-cerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42: 3594-3599.
• 55 Halim AB, Li Y, Stein E. et al. Low Concentrations of rhFVIIa or FEIBA Significantly and Rapidly Reverse the Anticoagulant Effect of Supratherapeutic Edoxaban. Poster at the ASH Congress??)). Dec. 10, 2011 San Diego:
• 56 Godier A, Miclot A, Le Bonniec B. et al. Evaluation of Prothrombin Complex Concentrate and Recombinant Activated Factor VII to Reverse Rivaroxaban in a Rabbit Model. Anesthesiology 2012; 116: 94-102.
• 57 Fukuda T, Honda Y, Kamisato C. et al. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost 2012; 107: 253-259.
• 58 Warkentin TE, Margetts P, Connolly SJ. et al. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012; 119: 2172-2174.
• 59 Levi MM, Eerenberg E, Löwenberg E. et al. Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management. Neth J Med 2010; 68: 68-76.
• 60 Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of non-inferiority randomized controlled trials. Arch Intern Med 2012; 172: 397-402.
• 61 Sié P, Samama CM, Godier A. et al. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: Thrombin or factor-Xa inhibitors. Recommendations of the Working Group on perioperative haemostasis and the French Study Group on thrombosis and haemostasis. Arch Cardiovasc Dis 2011; 104: 669-676.
• 62 Pernod G, Godier A, Gozalo C. et al. French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding and active bleeding). Thromb Res 2010; 126: e167-174.